Prediction is very difficult, especially about the future”; whether it is the Nobel laureate Niels Bohr or others who have ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Novo Nordisk is planning a new Phase III trial for CagriSema ... CagriSema combines the GLP-1 receptor agonist (GLP-1RA) ...

The approval was based on data from the randomized, double-blind, placebo-controlled FLOW trial (ClinicalTrials.gov Identifier: NCT03819153), which evaluated the effects of semaglutide, a ...

Only Novo Nordisk manufactures FDA-approved semaglutide medicines, like Ozempic. FLOW was an international, randomized, double-blind, parallel-group, placebo-controlled, event-driven superiority trial ...

Key Takeaways from the Metabolic Dysfunction-Associated Steatohepatitis Market Report According to DelveInsight's analysis, the market size for MASH was found to be USD 2.1 billion in the 7MM in 2023.

Novo Nordisk (NYSE ... with a strong focus on GLP-1 receptor agonists. The company's key products, including Ozempic (semaglutide) for diabetes and Wegovy (semaglutide) for obesity, have driven ...

Novo Nordisk (NVO) has been experiencing a challenging period, primarily due to regulatory pressures and mixed trial results. Recently, the Centers for Medicare & Medicaid Services (CMS) included Novo ...

In May 2024, Novo Nordisk released the full results from its clinical trial, which showed a 24% risk reduction in kidney- and cardiovascular-related mortality from the once-weekly semaglutide 1.0 ...

Novo Nordisk recently published favorable results from the FLOW renal outcomes trial, which found that Ozempic (semaglutide) 1.0 mg lowered the risk of kidney disease progression and kidney and ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO ... two brands of its leading GLP-1 agonist, semaglutide, which suppresses appetite and slows digestion to encourage weight loss.